Ab Initio connects to the Interwebs!

Ab Initio is pleased to announce the launch of its new website (www.ab-initio-pharma.com). As part of our brand awareness, Ab Initio's website reflects our business strategy and focus on supplying leading formulation R&D services to the Therapeutic and MedTech sectors.

We at Ab Initio Pharma know the challenges of taking an idea & transforming into an innovative therapeutic product. We provide SMEs & early stage researchers bespoke pharmaceutical drug delivery R&D & manufacturing solutions to help you navigate that pathway through to first in human trials & beyond.

With Headquarters conveniently located at the Professor Marie Bashir Centre in Camperdown, Sydney, Australia, our facility is purpose built & equipped with state-of-the-art technologies for pharmaceutical product R&D, GMP manufacturing, research & development as well as in vitro testings of formulation, device & packaging. Our company specialises in taking a lead compound or idea to final product ready for clinical trials & helping solve pharmaceutical problems. Ab Initio specialises in non-sterile dosage forms and has core strength in orally inhaled and nasal drug products as well as other aerosol-based technologies.

Prof Paul Young, CEO of Ab Initio said " The launch of our website marks an important milestone for our company as it provides a platform and entry point for existing and future partners as well as providing a source of information for those who visit us The website not only provides information regarding our capabilities but will allow people to keep up to date with news and upcoming events"

Ab Initio Pharma Ltd was founded in 2019. A spin-off by the University of Sydney, in partnership with Sydney Local Health Distinct & the peak industry body, ACRS, Ab Initio provides innovators across Australia & globally with a flexible platform to rapidly translate bench-top discoveries to clinical trial products.